Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04189614 · ClinicalTrials.gov registry record · Phase 1
An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer
A Phase 1 study of Cancer and Non-small Cell Lung Cancer (NSCLC), sponsored by AbbVie.
- Active
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
- 20
- Study locations
NCT04189614 is a Phase 1 study of Cancer and Non-small Cell Lung Cancer (NSCLC) that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 65 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT04189614, a Phase 1 study of Cancer and Non-small Cell Lung Cancer (NSCLC), is active but no longer recruiting, sponsored by AbbVie.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is being done to determine the efficacy and safety of cofetuzumab pelidotin in the PTK7-expressing, recurrent non-small cell lung cancer (NSCLC) population.
Conditions Studied
Interventions
- DRUG Cofetuzumab Pelidotin
Study Locations (20)
Florida
- Sylvester Comprehensive Cancer Center /ID# 216433 - Miami
- Moffitt Cancer Center /ID# 215101 - Tampa
Texas
- Oncology Consultants /ID# 215932 - Houston
- University of Texas MD Anderson Cancer Center /ID# 215876 - Houston
Other
- Rambam Health Care Campus /ID# 217536 - Haifa
- Rabin Medical Center /ID# 217537 - Petah Tikva
Seoul Teugbyeolsi
- Asan Medical Center /ID# 222280 - Seoul
- Samsung Medical Center /ID# 222906 - Seoul
Alabama
- University of Alabama at Birmingham - Main /ID# 213605 - Birmingham
Arkansas
- Highlands Oncology Group, PA /ID# 215383 - Springdale
California
- Duplicate_Stanford University School of Med /ID# 213450 - Stanford
Colorado
- Univ of Colorado Cancer Center /ID# 215295 - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2020-02-13 |
| Est. Completion | 2025-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04189614
The ClinicalTrials.gov registry entry for NCT04189614 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Cofetuzumab Pelidotin is the first listed.
NCT04189614 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Florida, Texas, Other.
Frequently Asked Questions
What is clinical trial NCT04189614 about?
NCT04189614 is a clinical study titled "An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer". This study is being done to determine the efficacy and safety of cofetuzumab pelidotin in the PTK7-expressing, recurrent non-small cell lung cancer (NSCLC) population.
What is the current status of trial NCT04189614?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2020-02-13. Estimated completion is 2025-12.
What conditions does trial NCT04189614 study?
This clinical trial studies the following conditions: Cancer, Non-small Cell Lung Cancer (NSCLC).
What interventions are being tested in trial NCT04189614?
The interventions under investigation include: Cofetuzumab Pelidotin (DRUG).
Who is sponsoring clinical trial NCT04189614?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04189614 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.